Takehiko Kamijo

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 14

Top Topics

Papillary Thyroid

Cell Proliferation

Dna Damage Response

Top Venues

Pediatric blood & cancer

Genes to cells : devoted to molecular & cellular mechanisms

This page only lists publications with an associated author ORCID identifier.

Publications

Ryu Okada, Hisanori Takenobu, Shunpei Satoh, Ryuichi P Sugino, Ritsuko Onuki, Masayuki Haruta, Kyosuke Mukae, Atsuko Nakazawa, Jesmin Akter, Miki Ohira, Takehiko Kamijo
L3MBTL2 maintains MYCN-amplified neuroblastoma cell proliferation through silencing NRIP3 and BRME1 genes. Genes to cells : devoted to molecular & cellular mechanisms (2024)
Akihiro Yoneda, Hiroyuki Shichino, Tomoro Hishiki, Kimikazu Matsumoto, Miki Ohira, Takehiko Kamijo, Tatsuo Kuroda, Toshinori Soejima, Atsuko Nakazawa, Tetsuya Takimoto, Isao Yokota, Satoshi Teramukai, Hideto Takahashi, Takashi Fukushima, Junichi Hara, Michio Kaneko, Hitoshi Ikeda, Tatsuro Tajiri, Hideo Mugishima, Akira Nakagawara
A nationwide phase II study of delayed local treatment for children with high-risk neuroblastoma: The Japan Children's Cancer Group Neuroblastoma Committee Trial JN-H-11. Pediatric blood & cancer 71 (6) (2024)
Akihiro Yoneda, Hiroyuki Shichino, Tomoro Hishiki, Kimikazu Matsumoto, Miki Ohira, Takehiko Kamijo, Tatsuo Kuroda, Toshinori Soejima, Atsuko Nakazawa, Tetsuya Takimoto, Isao Yokota, Satoshi Teramukai, Hideto Takahashi, Takashi Fukushima, Junichi Hara, Michio Kaneko, Hitoshi Ikeda, Tatsuro Tajiri, Hideo Mugishima, Akira Nakagawara
A nationwide phase II study of delayed local treatment for children with high-risk neuroblastoma: The Japan Children's Cancer Group Neuroblastoma Committee Trial JN-H-11. Pediatric blood & cancer 71 (6) (2024)
Akihiro Yoneda, Hiroyuki Shichino, Tomoro Hishiki, Kimikazu Matsumoto, Miki Ohira, Takehiko Kamijo, Tatsuo Kuroda, Toshinori Soejima, Atsuko Nakazawa, Tetsuya Takimoto, Isao Yokota, Satoshi Teramukai, Hideto Takahashi, Takashi Fukushima, Junichi Hara, Michio Kaneko, Hitoshi Ikeda, Tatsuro Tajiri, Hideo Mugishima, Akira Nakagawara
A nationwide phase II study of delayed local treatment for children with high-risk neuroblastoma: The Japan Children's Cancer Group Neuroblastoma Committee Trial JN-H-11. Pediatric blood & cancer 71 (6) (2024)
Akihiro Yoneda, Hiroyuki Shichino, Tomoro Hishiki, Kimikazu Matsumoto, Miki Ohira, Takehiko Kamijo, Tatsuo Kuroda, Toshinori Soejima, Atsuko Nakazawa, Tetsuya Takimoto, Isao Yokota, Satoshi Teramukai, Hideto Takahashi, Takashi Fukushima, Junichi Hara, Michio Kaneko, Hitoshi Ikeda, Tatsuro Tajiri, Hideo Mugishima, Akira Nakagawara
A nationwide phase II study of delayed local treatment for children with high-risk neuroblastoma: The Japan Children's Cancer Group Neuroblastoma Committee Trial JN-H-11. Pediatric blood & cancer (2024)
Noriyuki Nishimura, Toshiaki Ishida, Isao Yokota, Kimikazu Matsumoto, Hiroyuki Shichino, Hiroyuki Fujisaki, Takeo Sarashina, Takehiko Kamijo, Tetsuya Takimoto, Tomoko Iehara, Tatsuro Tajiri, null On Behalf Of The Jccg Neuroblastoma Committee
Minimal Residual Disease Detected by the 7NB-mRNAs ddPCR Assay Is Associated with Disease Progression in High-Risk Neuroblastoma Patients: A Prospective Multicenter Observational Study in Japan. Biology 12 (10) (2023)
Kiyohiro Ando, Yusuke Suenaga, Takehiko Kamijo
DNA Ligase 4 Contributes to Cell Proliferation against DNA-PK Inhibition in MYCN -Amplified Neuroblastoma IMR32 Cells. International journal of molecular sciences 24 (10) (2023)
Kyosuke Mukae, Hisanori Takenobu, Yuki Endo, Masayuki Haruta, Tianyuan Shi, Shunpei Satoh, Miki Ohira, Michinori Funato, Junya Toguchida, Kenji Osafune, Tatsutoshi Nakahata, Hiroaki Kanda, Takehiko Kamijo
Development of an osteosarcoma model with MYCN amplification and TP53 mutation in hiPS cell-derived neural crest cells. Cancer science (2023)
Kyosuke Mukae, Hisanori Takenobu, Yuki Endo, Masayuki Haruta, Tianyuan Shi, Shunpei Satoh, Miki Ohira, Michinori Funato, Junya Toguchida, Kenji Osafune, Tatsutoshi Nakahata, Hiroaki Kanda, Takehiko Kamijo
Development of an osteosarcoma model with MYCN amplification and TP53 mutation in hiPS cell-derived neural crest cells. Cancer science (2023)
Yoshitaka Shinno, Hisanori Takenobu, Ryuichi P Sugino, Yuki Endo, Ryu Okada, Masayuki Haruta, Shunpei Satoh, Kyosuke Mukae, Dilibaerguli Shaliman, Tomoko Wada, Jesmin Akter, Kiyohiro Ando, Atsuko Nakazawa, Hideo Yoshida, Miki Ohira, Tomoro Hishiki, Takehiko Kamijo
Polycomb EZH1 regulates cell cycle/5-fluorouracil sensitivity of neuroblastoma cells in concert with MYCN. Cancer science (2022)
Kevin Campbell, Pei-Chi Kao, Arlene Naranjo, Takehiko Kamijo, Ramya Ramanujachar, Wendy B London, Steven G DuBois
Clinical and biological features prognostic of survival after relapse or progression of INRGSS stage MS pattern neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project. Pediatric blood & cancer (2022)
Miki Ohira, Yohko Nakamura, Tetsuya Takimoto, Atsuko Nakazawa, Tomoro Hishiki, Kimikazu Matsumoto, Hiroyuki Shichino, Tomoko Iehara, Hiroki Nagase, Takashi Fukushima, Akihiro Yoneda, Tatsuro Tajiri, Akira Nakagawara, Takehiko Kamijo
Retrospective Analysis of INRG Clinical and Genomic Factors for 605 Neuroblastomas in Japan: A Report from the Japan Children's Cancer Group Neuroblastoma Committee (JCCG-JNBSG). Biomolecules 12 (1) (2021)
Jesmin Akter, Yutaka Katai, Parvin Sultana, Hisanori Takenobu, Masayuki Haruta, Ryuichi P Sugino, Kyosuke Mukae, Shunpei Satoh, Tomoko Wada, Miki Ohira, Kiyohiro Ando, Takehiko Kamijo
Loss of p53 suppresses replication stress-induced DNA damage in ATRX-deficient neuroblastoma. Oncogenesis 10 (11) (2021)
Jesmin Akter, Takehiko Kamijo
How Do Telomere Abnormalities Regulate the Biology of Neuroblastoma? Biomolecules 11 (8) (2021)